{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T10:08:16Z","timestamp":1790330896091,"version":"4.1.0"},"reference-count":191,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T00:00:00Z","timestamp":1629849600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["COVID-2020-12371817"],"award-info":[{"award-number":["COVID-2020-12371817"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007479","name":"Fondazione Cassa di Risparmio di Padova e Rovigo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007479","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.phrs.2021.105848","type":"journal-article","created":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T06:32:11Z","timestamp":1629959531000},"page":"105848","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Sex-tailored pharmacology and COVID-19: Next steps towards appropriateness and health equity"],"prefix":"10.1016","volume":"173","author":[{"given":"Andrea","family":"Spini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Giudice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0063-659X","authenticated-orcid":false,"given":"Vincenzo","family":"Brancaleone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Morgese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9841-7802","authenticated-orcid":false,"given":"Silvia","family":"De Francia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8235-9118","authenticated-orcid":false,"given":"Amelia","family":"Filippelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ruggieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Ziche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ortona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4820-4876","authenticated-orcid":false,"given":"Andrea","family":"Cignarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigia","family":"Trabace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2021.105848_bib1","unstructured":"The Sex, Gender and COVID-19 Project, Global Health 50\/50, (n.d.). \u3008https:\/\/globalhealth5050.org\/the-sex-gender-and-covid-19-project\/\u3009. (Accessed 28 June 2021)."},{"key":"10.1016\/j.phrs.2021.105848_bib2","first-page":"38","article-title":"Possible protective role of 17\u03b2-estradiol against COVID-19","volume":"1","author":"Khan","year":"2020","journal-title":"J. Allergy Infect. Dis."},{"key":"10.1016\/j.phrs.2021.105848_bib3","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1177\/1535370217718808","article-title":"Protective regulation of the ACE2\/ACE gene expression by estrogen in human atrial tissue from elderly men","volume":"242","author":"Bukowska","year":"2017","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.phrs.2021.105848_bib4","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ddr.21656","article-title":"Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics","volume":"81","author":"Gurwitz","year":"2020","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.phrs.2021.105848_bib5","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/cid\/ciaa329","article-title":"Is there an association between COVID-19 mortality and the renin-angiotensin system? A call for epidemiologic investigations","volume":"71","author":"Hanff","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.phrs.2021.105848_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/s41420-020-0276-1","article-title":"ACE2 expression and sex disparity in COVID-19","volume":"6","author":"Gagliardi","year":"2020","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.phrs.2021.105848_bib7","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3389\/fendo.2019.00420","article-title":"Estrogen promotes pro-resolving microglial behavior and phagocytic cell clearance through the actions of annexin A1","volume":"10","author":"Loiola","year":"2019","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.phrs.2021.105848_bib8","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s10753-018-0763-1","article-title":"SERMs promote anti-inflammatory signaling and phenotype of CD14+ cells","volume":"41","author":"Polari","year":"2018","journal-title":"Inflammation"},{"key":"10.1016\/j.phrs.2021.105848_bib9","doi-asserted-by":"crossref","first-page":"15224","DOI":"10.1038\/srep15224","article-title":"Estrogen accelerates the resolution of inflammation in macrophagic cells","volume":"5","author":"Villa","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2021.105848_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005840","article-title":"Progesterone-based therapy protects against influenza by promoting lung repair and recovery in females","volume":"12","author":"Hall","year":"2016","journal-title":"PLOS Pathog."},{"key":"10.1016\/j.phrs.2021.105848_bib11","unstructured":"Bollettino-sorveglianza-integrata-COVID-19_16-giugno-2021.pdf, (n.d.). \u3008https:\/\/www.epicentro.iss.it\/coronavirus\/bollettino\/Bollettino-sorveglianza-integrata-COVID-19_16-giugno-2021.pdf\u3009. (Accessed 28 June 2021)."},{"key":"10.1016\/j.phrs.2021.105848_bib12","article-title":"Estrogen and COVID-19 symptoms: associations in women from the COVID symptom study","author":"Costeira","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.phrs.2021.105848_bib13","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1186\/s12916-020-01851-z","article-title":"Evidence for treatment with estradiol for women with SARS-CoV-2 infection","volume":"18","author":"Seeland","year":"2020","journal-title":"BMC Med."},{"key":"10.1016\/j.phrs.2021.105848_bib14","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1093\/cid\/ciaa1022","article-title":"Potential influence of menstrual status and sex hormones on female severe acute respiratory syndrome coronavirus 2 infection: a cross-sectional multicenter study in Wuhan, China","volume":"72","author":"Ding","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.phrs.2021.105848_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2021.02.024","article-title":"Progesterone in addition to standard of care vs standard of care alone in the treatment of men hospitalized with moderate to severe COVID-19","author":"Ghandehari","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.phrs.2021.105848_bib16","first-page":"1437","article-title":"Selective estrogen receptor modulators: tissue specificity and clinical utility","volume":"9","author":"Martinkovich","year":"2014","journal-title":"Clin. Interv. Aging"},{"key":"10.1016\/j.phrs.2021.105848_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104488","article-title":"Drug repurposing for the treatment of COVID-19: pharmacological aspects and synthetic approaches","volume":"106","author":"Batalha","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.phrs.2021.105848_bib18","doi-asserted-by":"crossref","first-page":"4432","DOI":"10.1073\/pnas.96.8.4432","article-title":"Tamoxifen inhibits acidification in cells independent of the estrogen receptor","volume":"96","author":"Altan","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2021.105848_bib19","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s12275-021-0617-7","article-title":"Raloxifene as a treatment option for viral infections","volume":"59","author":"Hong","year":"2021","journal-title":"J. Microbiol."},{"key":"10.1016\/j.phrs.2021.105848_bib20","doi-asserted-by":"crossref","first-page":"41226","DOI":"10.1038\/srep41226","article-title":"Selective inhibition of Ebola entry with selective estrogen receptor modulators by disrupting the endolysosomal calcium","volume":"7","author":"Fan","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2021.105848_bib21","doi-asserted-by":"crossref","first-page":"L415","DOI":"10.1152\/ajplung.00398.2015","article-title":"Estrogenic compounds reduce influenza A virus replication in primary human nasal epithelial cells derived from female, but not male, donors","volume":"310","author":"Peretz","year":"2016","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.phrs.2021.105848_bib22","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.fob.2012.08.003","article-title":"Raloxifene inhibits hepatitis C virus infection and replication","volume":"2","author":"Takeda","year":"2012","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.phrs.2021.105848_bib23","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.21873\/invivo.12135","article-title":"Raloxifene and bazedoxifene could be promising candidates for preventing the COVID-19 related cytokine storm, ARDS and mortality","volume":"34","author":"Smetana","year":"2020","journal-title":"In Vivo"},{"key":"10.1016\/j.phrs.2021.105848_bib24","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1210\/jc.2018-00229","article-title":"Testosterone therapy in men with hypogonadism: an endocrine society* clinical practice guideline","volume":"103","author":"Bhasin","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2021.105848_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.110287","article-title":"Role of testosterone in COVID-19 patients \u2013 a double-edged sword?","volume":"144","author":"Hussain","year":"2020","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.phrs.2021.105848_bib26","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.metabol.2014.05.005","article-title":"Testosterone therapy, thrombosis, thrombophilia, cardiovascular events","volume":"63","author":"Glueck","year":"2014","journal-title":"Metabolism"},{"key":"10.1016\/j.phrs.2021.105848_bib27","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.trsl.2011.06.003","article-title":"Thrombotic events after starting exogenous testosterone in men with previously undiagnosed familial thrombophilia","volume":"158","author":"Glueck","year":"2011","journal-title":"Transl. Res."},{"key":"10.1016\/j.phrs.2021.105848_bib28","doi-asserted-by":"crossref","first-page":"i5968","DOI":"10.1136\/bmj.i5968","article-title":"Testosterone treatment and risk of venous thromboembolism: population based case-control study","volume":"355","author":"Martinez","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2021.105848_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01356","article-title":"Impact of androgens on inflammation-related lipid mediator biosynthesis in innate immune cells","volume":"11","author":"Pace","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2021.105848_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/jcm7120549","article-title":"Do androgens modulate the pathophysiological pathways of inflammation? Appraising the contemporary evidence","volume":"7","author":"Traish","year":"2018","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.phrs.2021.105848_bib31","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.trsl.2014.12.003","article-title":"Testosterone, thrombophilia, thrombosis","volume":"165","author":"Freedman","year":"2015","journal-title":"Transl. Res."},{"key":"10.1016\/j.phrs.2021.105848_bib32","doi-asserted-by":"crossref","first-page":"15812","DOI":"10.1073\/pnas.1309049110","article-title":"Hydrogen sulphide pathway contributes to the enhanced human platelet aggregation in hyperhomocysteinemia","volume":"110","author":"d\u2019Emmanuele di Villa Bianca","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2021.105848_bib33","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1111\/bph.12740","article-title":"Crucial role of androgen receptor in vascular H2S biosynthesis induced by testosterone","volume":"172","author":"Brancaleone","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2021.105848_bib34","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/183041","article-title":"Testosterone-induced effects on lipids and inflammation","volume":"2013","author":"Vodo","year":"2013","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.phrs.2021.105848_bib35","first-page":"116","article-title":"The relationship between testosterone and molecular markers of inflammation in older men","volume":"28","author":"Maggio","year":"2005","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.phrs.2021.105848_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154252","article-title":"Commentary: testosterone, a key hormone in the context of COVID-19 pandemic","volume":"108","author":"Pozzilli","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.phrs.2021.105848_bib37","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.3389\/fimmu.2018.01980","article-title":"Inefficient N2-like neutrophils are promoted by androgens during infection","volume":"9","author":"Scalerandi","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2021.105848_bib38","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nri2470","article-title":"Annexin A1 and glucocorticoids as effectors of the resolution of inflammation","volume":"9","author":"Perretti","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.phrs.2021.105848_bib39","doi-asserted-by":"crossref","DOI":"10.4081\/monaldi.2020.1389","article-title":"Gender differences in patients with COVID-19: a narrative review","volume":"90","author":"Ambrosino","year":"2020","journal-title":"Monaldi Arch. Chest Dis."},{"key":"10.1016\/j.phrs.2021.105848_bib40","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s13063-021-05137-4","article-title":"COVIDENZA \u2013 a prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with corona virus disease 2019 (COVID-19): a structured summary of a study protocol for a randomised controlled trial","volume":"22","author":"Wel\u00e9n","year":"2021","journal-title":"Trials"},{"key":"10.1016\/j.phrs.2021.105848_bib41","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.chest.2020.11.005","article-title":"Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019","volume":"159","author":"Jim\u00e9nez","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.phrs.2021.105848_bib42","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood.2020006520","article-title":"COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection","volume":"136","author":"Al-Samkari","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2021.105848_bib43","doi-asserted-by":"crossref","first-page":"e575","DOI":"10.1016\/S2352-3026(20)30216-7","article-title":"Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study","volume":"7","author":"Goshua","year":"2020","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.phrs.2021.105848_bib44","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.phrs.2017.01.004","article-title":"Balancing thromboembolic and bleeding risk with non-vitamin K antagonist oral anticoagulants (NOACs): a systematic review and meta-analysis on gender differences","volume":"117","author":"Proietti","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2021.105848_bib45","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.cjca.2018.04.019","article-title":"Variability in non-vitamin K antagonist oral anticoagulants dose adjustment in atrial fibrillation patients with renal dysfunction: the influence of renal function estimation formulae","volume":"34","author":"Andrade","year":"2018","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.phrs.2021.105848_bib46","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1124\/pharmrev.120.000206","article-title":"Sex-and gender-based pharmacological response to drugs","volume":"73","author":"Mauvais-Jarvis","year":"2021","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.phrs.2021.105848_bib47","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1093\/cvr\/cvab023","article-title":"COVID-19, the wake-up call for implementing sex and gender in cardiovascular disease","volume":"117","author":"Maas","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.phrs.2021.105848_bib48","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJM198907203210301","article-title":"Final report on the aspirin component of the ongoing physicians\u2019 health study","volume":"321","author":"Steering Committee of the Physicians\u2019 Health Study Research Group","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2021.105848_bib49","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa050613","article-title":"A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women","volume":"352","author":"Ridker","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2021.105848_bib50","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1111\/jth.15032","article-title":"Chronic therapeutic anticoagulation is associated with decreased thrombotic complications in SARS-CoV-2 infection","volume":"18","author":"Lachant","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.phrs.2021.105848_bib51","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/joim.13205","article-title":"Direct oral anticoagulant use and risk of severe COVID-19","volume":"289","author":"Flam","year":"2021","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.phrs.2021.105848_bib52","first-page":"1","article-title":"Heparin in COVID-19 patients is associated with reduced in-hospital mortality: the multicenter Italian CORIST study","author":"Castelnuovo","year":"2021","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.phrs.2021.105848_bib53","first-page":"1","article-title":"Use of low-molecular weight heparin, transfusion and mortality in COVID-19 patients not requiring ventilation","author":"Grandone","year":"2021","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.phrs.2021.105848_bib54","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1007\/s11239-020-02253-x","article-title":"Should we consider heparin prophylaxis in COVID-19 patients? a systematic review and meta-analysis","volume":"51","author":"Abdel-Maboud","year":"2021","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.phrs.2021.105848_bib55","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1016\/j.jacc.2020.04.031","volume":"75","author":"Bikdeli","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2021.105848_bib56","unstructured":"Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial, Abstract \u2013 Europe PMC, (n.d.). \u3008https:\/\/europepmc.org\/article\/med\/33865239\u3009. (Accessed 28 June 2021)."},{"key":"10.1016\/j.phrs.2021.105848_bib57","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1016\/S0140-6736(21)01203-4","article-title":"Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial","volume":"397","author":"Lopes","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2021.105848_bib58","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1182\/blood.2020010529","article-title":"Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry","volume":"137","author":"Giannis","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2021.105848_bib59","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41569-020-0360-5","article-title":"COVID-19 and the cardiovascular system","volume":"17","author":"Zheng","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.phrs.2021.105848_bib60","doi-asserted-by":"crossref","first-page":"m810","DOI":"10.1136\/bmj.m810","article-title":"Preventing a covid-19 pandemic","volume":"368","author":"Watkins","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2021.105848_bib61","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4103\/jgid.jgid_86_20","article-title":"The 2019\u20132020 novel coronavirus (severe acute respiratory syndrome coronavirus 2) pandemic: a joint American college of academic international medicine-world academic council of emergency medicine multidisciplinary COVID-19 working group consensus paper","volume":"12","author":"Stawicki","year":"2020","journal-title":"J. Glob. Infect. Dis."},{"key":"10.1016\/j.phrs.2021.105848_bib62","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","article-title":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2","volume":"111","author":"Ferrario","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2021.105848_bib63","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1111\/j.1523-1755.2005.00675.x","article-title":"Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors","volume":"68","author":"Ferrario","year":"2005","journal-title":"Kidney Int."},{"key":"10.1016\/j.phrs.2021.105848_bib64","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm1267","article-title":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus\u2013induced lung injury","volume":"11","author":"Kuba","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2021.105848_bib65","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature03712","article-title":"Angiotensin-converting enzyme 2 protects from severe acute lung failure","volume":"436","author":"Imai","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2021.105848_bib66","article-title":"Cardiovascular disease, drug therapy, and mortality in covid-19","volume":"382","author":"Mehra","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2021.105848_bib67","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/ajh\/hpy148","article-title":"Sex differences in hypertension: where we have been and where we are going","volume":"31","author":"Ramirez","year":"2018","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.phrs.2021.105848_bib68","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa2006923","article-title":"Renin\u2013angiotensin\u2013aldosterone system blockers and the risk of covid-19","volume":"382","author":"Mancia","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2021.105848_bib69","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(20)31030-8","article-title":"Use of renin\u2013angiotensin\u2013aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study","volume":"395","author":"de Abajo","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2021.105848_bib70","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamacardio.2020.1624","article-title":"Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China","volume":"5","author":"Li","year":"2020","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.phrs.2021.105848_bib71","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1080\/10641963.2020.1783549","article-title":"Is the use of ACE inb\/ARBs associated with higher in-hospital mortality in Covid-19 pneumonia patients?","volume":"42","author":"Sel\u00e7uk","year":"2020","journal-title":"Clin. Exp. Hypertens."},{"key":"10.1016\/j.phrs.2021.105848_bib72","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1164\/rccm.202002-0445OC","article-title":"COVID-19 with different severities: a multicenter study of clinical features","volume":"201","author":"Feng","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.phrs.2021.105848_bib73","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","article-title":"Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension","volume":"9","author":"Meng","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.phrs.2021.105848_bib74","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jinf.2020.05.052","article-title":"Estimation of renin-angiotensin-aldosterone-system (RAAS)-inhibitor effect on COVID-19 outcome: a meta-analysis","volume":"81","author":"Pirola","year":"2020","journal-title":"J. Infect."},{"key":"10.1016\/j.phrs.2021.105848_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104927","article-title":"ACEI\/ARB use and risk of infection or severity or mortality of COVID-19: a systematic review and meta-analysis","volume":"158","author":"Zhang","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2021.105848_bib76","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMe2020822","article-title":"Expression of concern: Mehra MR et al. Cardiovascular disease, drug therapy, and mortality in Covid-19. N. Engl. J. Med. DOI: 10.1056\/NEJMoa2007621","volume":"382","author":"Rubin","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2021.105848_bib77","first-page":"1824","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review","volume":"323","author":"Sanders","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2021.105848_bib78","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"PALM consortium study team, a randomized, controlled trial of Ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2021.105848_bib79","unstructured":"Lopinavir-Ritonavir_EN_17.07.2020.pdf, (n.d.). \u3008https:\/\/www.aifa.gov.it\/documents\/20142\/1267737\/Lopinavir-Ritonavir_EN_17.07.2020.pdf\u3009. (Accessed 28 June 2021)."},{"key":"10.1016\/j.phrs.2021.105848_bib80","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0243705","article-title":"Efficacy and harms of Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis","volume":"15","author":"Piscoya","year":"2020","journal-title":"PLOS ONE"},{"key":"10.1016\/j.phrs.2021.105848_bib81","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1001\/jama.2020.16337","article-title":"Efficacy of Remdesivir in COVID-19","volume":"324","author":"McCreary","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2021.105848_bib82","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2021.105848_bib83","article-title":"Efficacy and safety of lopinavir\/ritonavir for treatment of COVID-19: a systematic review and meta-analysis","volume":"5","author":"Alhumaid","year":"2020","journal-title":"Trop. Med. Infect. Dis."},{"key":"10.1016\/j.phrs.2021.105848_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.jiph.2021.03.015","article-title":"Efficacy and safety of lopinavir-ritonavir in COVID-19: A systematic review of randomized controlled trials.","author":"Patel","year":"2021","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.phrs.2021.105848_bib85","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.26256","article-title":"Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis","author":"Huang","year":"2021","journal-title":"J Med Virol"},{"key":"10.1016\/j.phrs.2021.105848_bib86","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-90551-6","article-title":"The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials.","author":"Hassanipour","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.phrs.2021.105848_bib87","doi-asserted-by":"crossref","DOI":"10.3390\/v10040184","article-title":"Arbidol (umifenovir): a broad-spectrum antiviral drug that inhibits medically important arthropod-borne flaviviruses","volume":"10","author":"Haviernik","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.phrs.2021.105848_bib88","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"10.1016\/j.phrs.2021.105848_bib89","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijid.2020.11.142","article-title":"Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multicenter, phase 3 clinical trial","volume":"103","author":"Udwadia","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.phrs.2021.105848_bib90","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/bies.201200099","article-title":"Sex influences immune responses to viruses, and efficacy of prophylaxis and treatments for viral diseases","volume":"34","author":"Klein","year":"2012","journal-title":"Bioessays"},{"key":"10.1016\/j.phrs.2021.105848_bib91","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1158\/2159-8290.CD-20-0941","article-title":"Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: a COVID-19 and cancer consortium (CCC19) cohort study","volume":"10","author":"Rivera","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phrs.2021.105848_bib92","doi-asserted-by":"crossref","DOI":"10.4414\/smw.2020.20446","article-title":"Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs","volume":"150","author":"Vernaz","year":"2020","journal-title":"Swiss Med. Wkly."},{"key":"10.1016\/j.phrs.2021.105848_bib93","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of covid-19 \u2013 final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2021.105848_bib94","article-title":"Efficacy and safety of remdesivir in hospitalized covid-19 patients: systematic review and meta-analysis including network meta-analysis","author":"Elsawah","year":"2020","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.phrs.2021.105848_bib95","unstructured":"Population-scale patient safety data reveal inequalities in adverse events before and during covid-19 pandemic, medRxiv, (n.d.). \u3008https:\/\/www.medrxiv.org\/content\/10.1101\/2021.01.17.21249988v1.full\u3009. (Accessed 28 June 2021)."},{"key":"10.1016\/j.phrs.2021.105848_bib96","doi-asserted-by":"crossref","unstructured":"Rapid COVID-19 vaccine development, Science, (n.d.). \u3008https:\/\/science.sciencemag.org\/content\/368\/6494\/945\u3009. (Accessed 28 June 2021).","DOI":"10.1126\/science.abb8923"},{"key":"10.1016\/j.phrs.2021.105848_bib97","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jama.2020.10245","article-title":"Monoclonal antibodies for prevention and treatment of COVID-19","volume":"324","author":"Marovich","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2021.105848_bib98","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-040129","article-title":"Sex difference in coronavirus disease (COVID-19): a systematic review and meta-analysis","volume":"10","author":"Abate","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.phrs.2021.105848_bib99","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41577-020-0312-7","article-title":"COVID-19: risk for cytokine targeting in chronic inflammatory diseases?","volume":"20","author":"Schett","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.phrs.2021.105848_bib100","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41584-020-0474-5","article-title":"Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications","volume":"16","author":"Merrill","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.phrs.2021.105848_bib101","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.phrs.2021.105848_bib102","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.3389\/fimmu.2018.01931","article-title":"Sex hormones determine immune response","volume":"9","author":"Taneja","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2021.105848_bib103","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41586-020-2700-3","article-title":"Sex differences in immune responses that underlie COVID-19 disease outcomes","author":"Takahashi","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2021.105848_bib104","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3390\/transplantology1020007","article-title":"Transplant drugs against SARS, MERS and COVID-19","volume":"1","author":"Hage","year":"2020","journal-title":"Transplantology"},{"key":"10.1016\/j.phrs.2021.105848_bib105","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1111\/liv.14552","article-title":"Low prevalence and disease severity of COVID-19 in post-liver transplant recipients-a single centre experience","volume":"40","author":"Verma","year":"2020","journal-title":"Liver Int."},{"key":"10.1016\/j.phrs.2021.105848_bib106","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1136\/gutjnl-2020-322620","article-title":"Modulating immunosuppression in liver transplant patients with COVID-19","volume":"70","author":"Rodriguez-Peralvarez","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2021.105848_bib107","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/infdis\/jiaa150","article-title":"Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia","volume":"221","author":"Wang","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.phrs.2021.105848_bib108","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jhep.2020.07.040","article-title":"Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients","volume":"74","author":"Colmenero","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phrs.2021.105848_bib109","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/jcph.123","article-title":"Sex differences in cyclosporine pharmacokinetics and ABCB1 gene expression in mononuclear blood cells in African American and Caucasian renal transplant recipients","volume":"53","author":"Tornatore","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2021.105848_bib110","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.genm.2011.01.003","article-title":"Gender differences in pharmacokinetics of tacrolimus and their clinical significance in kidney transplant recipients","volume":"8","author":"Velickovi\u0107-Radovanovi\u0107","year":"2011","journal-title":"Gend. Med."},{"key":"10.1016\/j.phrs.2021.105848_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2021.100716","article-title":"Pragmatic, open-label, single-center, randomized, phase II clinical trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus in patients with severe pneumonia secondary to COVID-19: the TACROVID trial protocol","volume":"21","author":"Solanich","year":"2021","journal-title":"Contemp. Clin. Trials Commun."},{"key":"10.1016\/j.phrs.2021.105848_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100591","volume":"28","author":"Guisado-Vasco","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.phrs.2021.105848_bib113","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.virusres.2014.02.010","article-title":"Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir","volume":"184","author":"Carbajo-Lozoya","year":"2014","journal-title":"Virus Res."},{"key":"10.1016\/j.phrs.2021.105848_bib114","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms8070977","article-title":"Calcineurin inhibitor-based immunosuppression and COVID-19: results from a multidisciplinary cohort of patients in Northern Italy","volume":"8","author":"Cavagna","year":"2020","journal-title":"Microorganisms"},{"key":"10.1016\/j.phrs.2021.105848_bib115","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13317-020-00141-1","article-title":"Association between autoimmune diseases and COVID-19 as assessed in both a test-negative case\u2013control and population case\u2013control design","volume":"11","author":"Murtas","year":"2020","journal-title":"Autoimmun. Highlights"},{"key":"10.1016\/j.phrs.2021.105848_bib116","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1016\/S2665-9913(20)30169-7","article-title":"Brescia rheumatology COVID-19 study group, COVID-19 in patients with rheumatic diseases in Northern Italy: a single-centre observational and case-control study","volume":"2","author":"Fredi","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.phrs.2021.105848_bib117","article-title":"Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors","author":"Jovani","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2021.105848_bib118","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2217\/imt-2020-0153","article-title":"How COVID-19 affects patients receiving anticytokine and JAK inhibitors in rheumatology and dermatology","volume":"12","author":"Jessica Chang","year":"2020","journal-title":"Immunotherapy"},{"key":"10.1016\/j.phrs.2021.105848_bib119","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/acr2.11148","article-title":"Experiences of patients with rheumatic diseases in the United States during early days of the COVID-19 pandemic","volume":"2","author":"Michaud","year":"2020","journal-title":"ACR Open Rheumatol."},{"key":"10.1016\/j.phrs.2021.105848_bib120","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1136\/annrheumdis-2020-217888","article-title":"Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US \u201chot spot","volume":"79","author":"D\u2019Silva","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2021.105848_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102575","article-title":"SARS-CoV-2 infection among patients with systemic autoimmune diseases","volume":"19","author":"Emmi","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.phrs.2021.105848_bib122","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.3899\/jrheum.200507","article-title":"Incidence and clinical course of COVID-19 in patients with connective tissue diseases: a descriptive observational analysis","volume":"47","author":"Favalli","year":"2020","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.phrs.2021.105848_bib123","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/annrheumdis-2020-217424","article-title":"Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies","volume":"79","author":"Monti","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2021.105848_bib124","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc2009567","article-title":"Covid-19 in immune-mediated inflammatory diseases \u2014 case series from New York","author":"Haberman","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2021.105848_bib125","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","article-title":"COVID-19 global rheumatology alliance, characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry","volume":"79","author":"Gianfrancesco","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2021.105848_bib126","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.3389\/fonc.2019.01186","article-title":"Mechanisms underlying the anti-inflammatory and immunosuppressive activity of ruxolitinib","volume":"9","author":"Elli","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.phrs.2021.105848_bib127","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1038\/s41375-019-0379-y","article-title":"Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NF\u03baB signaling","volume":"33","author":"Fisher","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.phrs.2021.105848_bib128","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1128\/AAC.02496-13","article-title":"Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro","volume":"58","author":"Gavegnano","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.phrs.2021.105848_bib129","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.nbd.2016.02.007","article-title":"The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model","volume":"92","author":"Haile","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.phrs.2021.105848_bib130","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe4724","article-title":"JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality","volume":"7","author":"Stebbing","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.phrs.2021.105848_bib131","article-title":"JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis","author":"Chen","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.phrs.2021.105848_bib132","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12879-020-05730-z","article-title":"JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis","volume":"21","author":"Walz","year":"2021","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.phrs.2021.105848_bib133","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2101643","article-title":"STOP-COVID trial investigators, tofacitinib in patients hospitalized with covid-19 pneumonia","author":"Guimar\u00e3es","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2021.105848_bib134","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3389\/fphar.2020.00857","article-title":"Combination of ruxolitinib and eculizumab for treatment of severe SARS-CoV-2-related acute respiratory distress syndrome: a controlled study","volume":"11","author":"Giudice","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phrs.2021.105848_bib135","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"ACTT-2 study group members, baricitinib plus Remdesivir for hospitalized adults with Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2021.105848_bib136","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ajpath.2020.08.009","article-title":"Immunopathology of hyperinflammation in COVID-19","volume":"191","author":"Gustine","year":"2021","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.phrs.2021.105848_bib137","doi-asserted-by":"crossref","DOI":"10.1177\/1753466620933508","article-title":"Lung under attack by COVID-19-induced cytokine storm: pathogenic mechanisms and therapeutic implications","volume":"14","author":"Pelaia","year":"2020","journal-title":"Ther. Adv. Respir. Dis."},{"key":"10.1016\/j.phrs.2021.105848_bib138","first-page":"1","article-title":"Efficacy and safety of systematic corticosteroids among severe COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials","volume":"6","author":"Ma","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.phrs.2021.105848_bib139","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01332","article-title":"Glucocorticoids, sex hormones, and immunity","volume":"9","author":"Bereshchenko","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2021.105848_bib140","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jama.2020.17023","article-title":"Association between administration of systemic corticosteroids and mortality among critically Ill patients with COVID-19: a meta-analysis","volume":"324","author":"WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2021.105848_bib141","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1186\/s13054-020-03340-4","article-title":"Corticosteroid therapy for coronavirus disease 2019-related acute respiratory distress syndrome: a cohort study with propensity score analysis","volume":"24","author":"Wu","year":"2020","journal-title":"Crit. Care"},{"key":"10.1016\/j.phrs.2021.105848_bib142","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13054-020-03422-3","article-title":"Early corticosteroids are associated with lower mortality in critically ill patients with COVID-19: a cohort study","volume":"25","author":"Monedero","year":"2021","journal-title":"Crit. Care"},{"key":"10.1016\/j.phrs.2021.105848_bib143","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1517\/14728222.11.5.613","article-title":"The IL-6\/sIL-6R complex as a novel target for therapeutic approaches","volume":"11","author":"Rose-John","year":"2007","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.phrs.2021.105848_bib144","doi-asserted-by":"crossref","first-page":"10970","DOI":"10.1073\/pnas.2005615117","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"117","author":"Xu","year":"2020","journal-title":"PNAS"},{"key":"10.1016\/j.phrs.2021.105848_bib145","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/jamainternmed.2020.6252","article-title":"STOP-COVID investigators, association between early treatment with tocilizumab and mortality among critically Ill patients With COVID-19","volume":"181","author":"Gupta","year":"2021","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.phrs.2021.105848_bib146","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102568","article-title":"Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy","volume":"19","author":"Toniati","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.phrs.2021.105848_bib147","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamainternmed.2020.6820","article-title":"Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial","volume":"181","author":"Hermine","year":"2021","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.phrs.2021.105848_bib148","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1001\/jamainternmed.2020.6615","article-title":"RCT-TCZ-COVID-19 study group, effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial","volume":"181","author":"Salvarani","year":"2021","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.phrs.2021.105848_bib149","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S2213-2600(21)00099-0","article-title":"Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Lescure","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.phrs.2021.105848_bib150","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.66125","article-title":"An open label trial of anakinra to prevent respiratory failure in COVID-19","volume":"10","author":"Kyriazopoulou","year":"2021","journal-title":"eLife"},{"key":"10.1016\/j.phrs.2021.105848_bib151","doi-asserted-by":"crossref","first-page":"e325","DOI":"10.1016\/S2665-9913(20)30127-2","article-title":"Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study","volume":"2","author":"Cavalli","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.phrs.2021.105848_bib152","series-title":"Medicines For Women","first-page":"41","article-title":"Effects of sex differences in the pharmacokinetics of drugs and their impact on the safety of medicines in women","author":"Fadiran","year":"2015"},{"key":"10.1016\/j.phrs.2021.105848_bib153","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.phrs.2021.105848_bib154","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/ajg.2013.171","article-title":"Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease","volume":"108","author":"Gisbert","year":"2013","journal-title":"Off. J. Am. Coll. Gastroenterol. ACG"},{"key":"10.1016\/j.phrs.2021.105848_bib155","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1128\/CDLI.8.4.806-810.2001","article-title":"Enhancement of splenic-macrophage Fc\u03b3 receptor expression by treatment with estrogens","volume":"8","author":"Gomez","year":"2001","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"10.1016\/j.phrs.2021.105848_bib156","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1006\/clin.1998.4602","article-title":"Treatment with progesterone analogues decreases macrophage Fc\u03b3 receptors expression","volume":"89","author":"Gomez","year":"1998","journal-title":"Clin. Immunol. Immunopathol."},{"key":"10.1016\/j.phrs.2021.105848_bib157","article-title":"Clinical efficacy and safety of angiogenesis inhibitors: sex differences and current challenges","author":"Cignarella","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.phrs.2021.105848_bib158","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1177\/0091270009350623","article-title":"Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis","volume":"50","author":"Frey","year":"2010","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2021.105848_bib159","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2011-09-380949","article-title":"The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL","volume":"119","author":"M\u00fcller","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2021.105848_bib160","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2012-eular.256","article-title":"AB0256 sex difference in response to rituximab in rheumatoid arthritis patients","volume":"71","author":"Khan","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2021.105848_bib161","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1146\/annurev-cellbio-100616-060718","article-title":"Sex and gender differences in the outcomes of vaccination over the life course","volume":"33","author":"Flanagan","year":"2017","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"10.1016\/j.phrs.2021.105848_bib162","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1473-3099(10)70049-9","article-title":"The Xs and Y of immune responses to viral vaccines","volume":"10","author":"Klein","year":"2010","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.phrs.2021.105848_bib163","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1001\/archinternmed.2008.513","article-title":"Walter reed health care system influenza vaccine consortium, half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses","volume":"168","author":"Engler","year":"2008","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.phrs.2021.105848_bib164","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3390\/vaccines9050522","article-title":"The gender impact assessment among healthcare workers in the SARS-CoV-2 vaccination-an analysis of serological response and side effects","volume":"9","author":"Di Resta","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.phrs.2021.105848_bib165","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"COVE study group, efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2021.105848_bib166","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2021.105848_bib167","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-020-01194-5","article-title":"T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1\/2 clinical trial","volume":"27","author":"Ewer","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2021.105848_bib168","unstructured":"D.Y. Logunov, Safety and Efficacy of an rAd26 and rAd5 Vector-Based Heterologous Prime-Boost Covid-19 Vaccine: An Interim Analysis of a Randomised Controlled Phase 3 Trial in Russia, 397, 2021, p. 11."},{"key":"10.1016\/j.phrs.2021.105848_bib169","unstructured":"Rapporto vaccini, (n.d.). \u3008https:\/\/aifa.gov.it\/rapporto-vaccini\u3009. (Accessed 28 June 2021)."},{"key":"10.1016\/j.phrs.2021.105848_bib170","unstructured":"Rapporto_sorveglianza_vaccini_COVID-19_3.pdf, (n.d.). \u3008https:\/\/www.aifa.gov.it\/documents\/20142\/1315190\/Rapporto_sorveglianza_vaccini_COVID-19_3.pdf\u3009. (Accessed 28 June 2021)."},{"key":"10.1016\/j.phrs.2021.105848_bib171","doi-asserted-by":"crossref","DOI":"10.15585\/mmwr.mm7008e3","article-title":"First month of COVID-19 vaccine safety monitoring \u2014 United States, december 14, 2020\u2013january 13, 2021","volume":"70","author":"Gee","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.phrs.2021.105848_bib172","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.jaci.2018.12.1003","article-title":"Anaphylaxis after vaccination reported to the vaccine adverse event reporting system, 1990-2016","volume":"143","author":"Su","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.phrs.2021.105848_bib173","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.1016\/j.vaccine.2013.09.066","article-title":"Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: reports to VAERS","volume":"31","author":"Halsey","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.phrs.2021.105848_bib174","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3390\/vaccines9040393","article-title":"Analysis of thrombotic adverse reactions of COVID-19 AstraZeneca vaccine reported to EudraVigilance database","volume":"9","author":"Tobaiqy","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.phrs.2021.105848_bib175","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1056\/NEJMoa2105385","article-title":"Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Scully","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2021.105848_bib176","unstructured":"A. Ruggieri, S. Anticoli, A. D\u2019Ambrosio, L. Giordani, M. Viora, The Influence of Sex and Gender on Immunity, Infection and Vaccination, (n.d.), p. 7."},{"key":"10.1016\/j.phrs.2021.105848_bib177","doi-asserted-by":"crossref","first-page":"m2107","DOI":"10.1136\/bmj.m2107","article-title":"UK obstetric surveillance system SARS-CoV-2 infection in pregnancy collaborative group, characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study","volume":"369","author":"Knight","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2021.105848_bib178","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1152\/physrev.00024.2020","article-title":"Pregnancy and COVID-19","volume":"101","author":"Wastnedge","year":"2021","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.phrs.2021.105848_bib179","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.bbrc.2020.12.064","article-title":"Comprehensive analysis of COVID-19 during pregnancy","volume":"538","author":"Moore","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2021.105848_bib180","doi-asserted-by":"crossref","first-page":"e884","DOI":"10.1016\/S2352-3026(20)30327-6","article-title":"Safety of direct oral anticoagulant exposure during pregnancy: a retrospective cohort study","volume":"7","author":"Beyer-Westendorf","year":"2020","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.phrs.2021.105848_bib181","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.tem.2020.11.004","article-title":"Sex and COVID-19: a protective role for reproductive steroids","volume":"32","author":"Pinna","year":"2021","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2021.105848_bib182","first-page":"4","volume":"7","author":"Jin","year":"2020","journal-title":"Mil. Med. Res."},{"key":"10.1016\/j.phrs.2021.105848_bib183","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105056","article-title":"Chinese herbal medicine for coronavirus disease 2019: a systematic review and meta-analysis","volume":"160","author":"Xiong","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2021.105848_bib184","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.583450","article-title":"Chinese herbal medicine used with or without conventional therapy for COVID-19: an evidence review of clinical studies","volume":"11","author":"Liang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phrs.2021.105848_bib185","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105046","article-title":"The database-based strategy may overstate the potential effects of traditional Chinese medicine against COVID-19","volume":"159","author":"Huang","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2021.105848_bib186","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2021.153531","article-title":"Association between use of Qingfei Paidu Tang and mortality in hospitalized patients with COVID-19: a national retrospective registry study","volume":"85","author":"Zhang","year":"2021","journal-title":"Phytomedicine"},{"key":"10.1016\/j.phrs.2021.105848_bib187","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104989","article-title":"Databases for facilitating mechanistic investigations of traditional Chinese medicines against COVID-19","volume":"159","author":"Jiang","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2021.105848_bib188","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1142\/S0192415X17500756","article-title":"Estrogenic potentials of traditional Chinese medicine","volume":"45","author":"Kiyama","year":"2017","journal-title":"Am. J. Chin. Med."},{"key":"10.1016\/j.phrs.2021.105848_bib189","unstructured":"Clinical Trial Explores the Use of Traditional Chinese Medicine Against COVID-19 > News > USC Dornsife, (n.d.). \u3008https:\/\/dornsife.usc.edu\/news\/stories\/3417\/traditional-chinese-medicine-xuanfei-baidu-for-covid-19.%20Accessed%20July%209,%202021\u3009. (Accessed 9 July 2021)."},{"key":"10.1016\/j.phrs.2021.105848_bib190","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105074","article-title":"Analysis on the current quality standards of Chinese materia medica used in COVID-19 prevention and treatment","volume":"160","author":"Shi","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2021.105848_bib191","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2021.111998","article-title":"Inhibition of drug-metabolizing enzymes by Qingfei Paidu decoction: implication of herb-drug interactions in COVID-19 pharmacotherapy","volume":"149","author":"Zhang","year":"2021","journal-title":"Food Chem. Toxicol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821004321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821004321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T01:48:17Z","timestamp":1734400097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661821004321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":191,"alternative-id":["S1043661821004321"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105848","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sex-tailored pharmacology and COVID-19: Next steps towards appropriateness and health equity","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105848","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"105848"}}